ExpreS2ion Biotech Holding Feed

	Tid*
2025-02-06	08:30	Bokslutskommuniké 2024
2024-11-14	-	Kvartalsrapport 2024-Q3
2024-10-30	-	Split EXPRS2 40:1
2024-08-15	-	Kvartalsrapport 2024-Q2
2024-06-07	-	X-dag ordinarie utdelning EXPRS2 0.00 SEK
2024-06-05	-	Årsstämma
2024-05-16	-	Kvartalsrapport 2024-Q1
2024-02-08	-	Bokslutskommuniké 2023
2023-11-16	-	Kvartalsrapport 2023-Q3
2023-08-17	-	Kvartalsrapport 2023-Q2
2023-05-25	-	X-dag ordinarie utdelning EXPRS2 0.00 SEK
2023-05-24	-	Årsstämma
2023-05-16	-	Kvartalsrapport 2023-Q1
2023-03-23	-	Extra Bolagsstämma 2023
2023-02-09	-	Bokslutskommuniké 2022
2022-11-17	-	Kvartalsrapport 2022-Q3
2022-08-18	-	Kvartalsrapport 2022-Q2
2022-05-31	-	Kvartalsrapport 2022-Q1
2022-05-27	-	X-dag ordinarie utdelning EXPRS2 0.00 SEK
2022-05-25	-	Årsstämma
2022-02-24	-	Bokslutskommuniké 2021
2021-11-18	-	Kvartalsrapport 2021-Q3
2021-08-19	-	Kvartalsrapport 2021-Q2
2021-05-27	-	X-dag ordinarie utdelning EXPRS2 0.00 SEK
2021-05-26	-	Årsstämma
2021-05-19	-	Kvartalsrapport 2021-Q1
2021-02-25	-	Bokslutskommuniké 2020
2020-11-19	-	Kvartalsrapport 2020-Q3
2020-09-23	-	Extra Bolagsstämma 2020
2020-08-20	-	Kvartalsrapport 2020-Q2
2020-05-27	-	X-dag ordinarie utdelning EXPRS2 0.00 SEK
2020-05-26	-	Årsstämma
2020-05-20	-	Kvartalsrapport 2020-Q1
2020-02-28	-	Bokslutskommuniké 2019
2019-11-14	-	Kvartalsrapport 2019-Q3
2019-08-22	-	Kvartalsrapport 2019-Q2
2019-05-24	-	X-dag ordinarie utdelning EXPRS2 0.00 SEK
2019-05-23	-	Årsstämma
2019-05-16	-	Kvartalsrapport 2019-Q1
2019-02-28	-	Bokslutskommuniké 2018
2018-11-22	-	Kvartalsrapport 2018-Q3
2018-08-24	-	Kvartalsrapport 2018-Q2
2018-05-25	-	X-dag ordinarie utdelning EXPRS2 0.00 SEK
2018-05-24	-	Årsstämma
2018-05-17	-	Kvartalsrapport 2018-Q1
2018-02-07	-	Bokslutskommuniké 2017
2017-11-30	-	Kvartalsrapport 2017-Q3
2017-08-31	-	Kvartalsrapport 2017-Q2
2017-06-01	-	X-dag ordinarie utdelning EXPRS2 0.00 SEK
2017-05-31	-	Årsstämma
2017-05-24	-	Kvartalsrapport 2017-Q1
2017-04-19	-	Extra Bolagsstämma 2017
2017-02-28	-	Bokslutskommuniké 2016
2016-11-08	-	Kvartalsrapport 2016-Q3
2016-08-31	-	Kvartalsrapport 2016-Q2

Land	Danmark
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Bioteknik

2024-12-11 12:10:00 ExpreS2ion Biotechnologies: Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine 29,60 SEK | +23,85% | 2,02 MSEK

2024-12-11 10:00:00 ExpreS2ion Biotechnologies: Analysguiden Publishes Research Report on ExpreS2ion Biotech with Price Target of SEK 91 29,60 SEK | +23,85% | 2,02 MSEK

2024-12-06 15:00:00 ExpreS2ion Biotechnologies: Warrants of series TO 10 were exercised to approximately 69 percent and ExpreS2ion receives approximately SEK 10 million 21,25 SEK | -3,85% | 0,49 MSEK

2024-12-02 16:12:10 ExpreS2ion Biotechnologies: ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer 19,96 SEK | -4,27% | 0,69 MSEK

2024-12-02 12:45:00 ExpreS2ion Biotechnologies: ExpreS2ion publishes video presentations from Biostock Life Science Summit and Analysguiden Stora Aktiedagarna 19,96 SEK | -4,27% | 0,69 MSEK

2024-12-02 09:30:00 ExpreS2ion Biotechnologies: Last day of trading in warrants of series TO 10 in Expres2ion Biotech Holding AB is today, 2 December 2024 19,96 SEK | -4,27% | 0,69 MSEK

2024-11-21 08:45:00 ExpreS2ion Biotechnologies: Full commitments from members of ExpreS2ion's Board and Management holding warrants of series TO 10 19,90 SEK | -5,01% | 0,11 MSEK

2024-11-20 08:30:00 ExpreS2ion Biotechnologies: ExpreS2ion announces the start of the exercise period for warrants of series TO 10 20,95 SEK | 0,00% | 0,38 MSEK

2024-11-18 11:00:00 ExpreS2ion Biotechnologies: ExpreS2ion to present in upcoming investor and scientific events 21,45 SEK | -1,38% | 0,17 MSEK

2024-11-14 19:47:34 ExpreS2ion Biotechnologies: ExpreS2ion announces TO 10 warrant exercise price and start of exercise period 21,75 SEK | -8,23% | 1,04 MSEK

2024-11-14 08:53:15 ExpreS2ion Biotechnologies: Correction: ExpreS2ion announces financial results for the third quarter of 2024 23,70 SEK | -7,06% | 0,27 MSEK

2024-11-14 08:30:00 ExpreS2ion Biotechnologies: ExpreS2ion announces financial results for the third quarter of 2024 23,70 SEK | -7,06% | 0,27 MSEK

2024-11-12 14:00:00 ExpreS2ion Biotechnologies: ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I002 24,85 SEK | -1,19% | 1,32 MSEK

2024-11-05 15:21:46 ExpreS2ion Biotechnologies: ExpreS2ion CEO talks to BioStock about partnering efforts at BIO-Europe 27,00 SEK | +0,93% | 0,47 MSEK

2024-11-05 08:15:00 ExpreS2ion Biotechnologies: ExpreS2ion CEO talking to BioStock about partnering efforts at BIO-Europe 27,00 SEK | +0,93% | 0,47 MSEK

2024-10-31 12:00:00 ExpreS2ion Biotechnologies: ExpreS2ion to present in upcoming investor and scientific events 30,00 SEK | -4,47% | 0,42 MSEK

2024-10-24 12:00:00 ExpreS2ion Biotechnologies: The Board of Directors of ExpreS2ion Biotech Holding AB (publ) has resolved on the record date for the reverse share split 34,64 SEK | -0,57%

2024-10-21 11:00:00 ExpreS2ion Biotechnologies: Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ) 35,28 SEK | -1,56% | 0,16 MSEK

2024-10-16 13:17:13 ExpreS2ion Biotechnologies: ExpreS2ion and Serum Institute of India have entered in a term sheet regarding proposed development and commercialisation of novel malaria vaccines 37,36 SEK | +8,60% | 2,42 MSEK

2024-09-19 09:15:00 ExpreS2ion Biotechnologies: Notice to attend the Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ) 42,08 SEK | -9,78% | 1,56 MSEK

2024-09-19 09:15:00 ExpreS2ion Biotechnologies: Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB (publ) 42,08 SEK | -9,78% | 1,56 MSEK

2024-09-10 14:00:00 ExpreS2ion Biotechnologies: ExpreS2ion to present in upcoming investor events 34,16 SEK | +1,79% | 0,11 MSEK

2024-08-23 12:45:00 ExpreS2ion Biotechnologies: ExpreS2ion announces publication of sponsored research reports 37,96 SEK | +1,28% | 0,22 MSEK

2024-08-15 08:30:00 ExpreS2ion Biotechnologies: ExpreS2ion announces financial results for the second quarter of 2024 39,12 SEK | +4,04% | 0,17 MSEK

2024-08-06 16:18:07 ExpreS2ion Biotechnologies: ExpreS2ion submits Clinical Trial Application (CTA) to conduct Phase I study of ES2B-C001, an innovative therapeutic breast cancer vaccine 35,28 SEK | +2,56% | 0,19 MSEK

2024-07-05 13:06:29 ExpreS2ion Biotechnologies: ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue 44,64 SEK | -0,18% | 0,17 MSEK

2024-07-03 12:30:00 ExpreS2ion Biotechnologies: ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens 48,00 SEK | +13,42% | 0,70 MSEK

2024-07-01 13:20:00 ExpreS2ion Biotechnologies: ExpreS2ion announces final outcome of its rights issue 46,16 SEK | -0,52% | 0,19 MSEK

2024-06-26 09:00:00 ExpreS2ion Biotechnologies: Rights issue subscription period ending 27 June 2024; subscription possible via form 46,88 SEK | +2,81% | 0,48 MSEK

2024-06-24 15:00:00 ExpreS2ion Biotechnologies: ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting 46,40 SEK | +7,41% | 0,64 MSEK

2024-06-21 11:30:00 ExpreS2ion Biotechnologies: Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine

2024-06-18 13:00:00 ExpreS2ion Biotechnologies: ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine 42,96 SEK | -3,76% | 0,38 MSEK

2024-06-12 08:45:00 ExpreS2ion Biotechnologies: The subscription period in ExpreS2ion's rights issue begins today 43,52 SEK | -1,81% | 0,23 MSEK

2024-06-10 14:00:00 ExpreS2ion Biotechnologies: ExpreS2ion to present in upcoming investor and scientific events 44,32 SEK | -3,65% | 0,10 MSEK

2024-06-05 16:40:00 ExpreS2ion Biotechnologies: ExpreS2ion publishes prospectus in connection with its rights issue of units 46,83 SEK | +0,88% | 0,14 MSEK

2024-06-05 11:30:00 ExpreS2ion Biotechnologies: Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 5 June 2024 46,83 SEK | +0,88% | 0,14 MSEK

2024-05-16 08:30:00 ExpreS2ion Biotechnologies: ExpreS2ion announces financial results for the first quarter of 2024 48,61 SEK | -1,25% | 0,19 MSEK

2024-05-15 15:17:54 ExpreS2ion Biotechnologies: ExpreS2ion to present in spring investor events 49,22 SEK | -0,14% | 0,12 MSEK

2024-05-08 12:05:00 ExpreS2ion Biotechnologies: ExpreS2ion annual report for 2023 published 50,59 SEK | -0,27% | 0,01 MSEK

2024-05-03 10:30:00 ExpreS2ion Biotechnologies: Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ) 49,70 SEK | -45,34% | 2,19 MSEK

2024-05-03 10:30:00 ExpreS2ion Biotechnologies: Kallelse till årsstämma i ExpreS2ion Biotech Holding AB (publ) 49,70 SEK | -45,34% | 2,19 MSEK

2024-05-02 21:23:56 ExpreS2ion Biotechnologies: ExpreS2ion announces a rights issue of units of approximately SEK 60 million 49,70 SEK | -45,34% | 2,19 MSEK

2024-04-23 14:20:23 ExpreS2ion Biotechnologies: ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS 102,38 SEK | +7,73% | 1,69 MSEK

2024-04-16 16:40:00 ExpreS2ion Biotechnologies: ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023 92,64 SEK | +29,05% | 1,15 MSEK

2024-04-16 14:29:24 ExpreS2ion Biotechnologies: ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate 92,64 SEK | +29,05% | 1,15 MSEK

2024-04-15 15:00:00 ExpreS2ion Biotechnologies: ExpreS2ion to present in investor and R&D events in March 71,78 SEK | -4,11% | 0,14 MSEK

2024-02-29 13:30:00 ExpreS2ion Biotechnologies: ExpreS2ion to present in investor and R&D events in March 100,67 SEK | +4,06% | 0,70 MSEK

2024-02-21 09:00:00 ExpreS2ion Biotechnologies: ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine 109,39 SEK | +2,56% | 0,59 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

ExpreS2ion Biotech Holding

Kalender

Beskrivning

ExpreS2ion Biotech Holding

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden